INVOKANA Market

“INVOKANA Market Size, Forecast, and Market Insight − 2032” report provides comprehensive insights about INVOKANA for Diabetic Kidney Disease (DKD) in the seven major markets. A detailed picture of the INVOKANA for DKD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the INVOKANA for DKD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the INVOKANA market forecast analysis for DKD in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in DKD.

Drug Summary

INVOKANA (canagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is indicated as an adjunct to diet and exercise to lower blood glucose in adults with T2D to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with T2D who have known cardiovascular disease and to reduce the risk of end-stage kidney disease (ESKD), worsening of kidney function, cardiovascular death, and hospitalization for heart failure in adults with T2D and diabetic nephropathy with a certain amount of protein in the urine. By inhibiting SGLT2, canagliflozin reduces the re-absorption of filtered glucose, lowers the renal threshold for glucose (RTG), and increases urinary glucose excretion (UGE). Canagliflozin increases the delivery of sodium to the distal tubule by blocking SGLT2-dependent glucose and sodium re-absorption. This is believed to increase tubuloglomerular feedback and reduce intraglomerular pressure.

INVOKAMET contains two prescription medicines: INVOKANA and metformin hydrochloride (GLUCOPHAGE). INVOKAMET XR contains two prescription medicines called INVOKANA and metformin hydrochloride extended-release (GLUMETZA). INVOKAMET or INVOKAMET XR can be used along with diet and exercise to lower blood sugar (glucose) in adults with type 2 diabetes; in adults with type 2 diabetes who have known cardiovascular disease and canagliflozin is needed to reduce the risk of major cardiovascular events such as heart attack, stroke, or death; in adults with type 2 diabetes and diabetic kidney disease (nephropathy) with a certain amount of protein in the urine, and canagliflozin is needed to reduce the risk of end-stage kidney disease (ESKD), worsening of kidney function, cardiovascular death, and hospitalization for heart failure.

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the INVOKANA description, mechanism of action, dosage and administration, research and development activities in Diabetic Kidney Disease (DKD).
• Elaborated details on INVOKANA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the INVOKANA research and development activities in DKD across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around INVOKANA.
• The report contains forecasted sales of INVOKANA for DKD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DKD.
• The report also features the SWOT analysis with analyst views for INVOKANA in DKD.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

INVOKANA Analytical Perspective by DelveInsight

• In-depth INVOKANA Market Assessment

This report provides a detailed market assessment of INVOKANA for Diabetic Kidney Disease (DKD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• INVOKANA Clinical Assessment

The report provides the clinical trials information of INVOKANA for Diabetic Kidney Disease (DKD) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights  

• In the coming years, the market scenario for Diabetic Kidney Disease (DKD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence INVOKANA dominance.
• Other emerging products for DKD are expected to give tough market competition to INVOKANA and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of INVOKANA in DKD.
• Our in-depth analysis of the forecasted sales data of INVOKANA from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the INVOKANA in DKD. 

Key Questions

• What is the product type, route of administration and mechanism of action of INVOKANA?
• What is the clinical trial status of the study related to INVOKANA in Diabetic Kidney Disease (DKD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the INVOKANA development?
• What are the key designations that have been granted to INVOKANA for DKD?
• What is the forecasted market scenario of INVOKANA for DKD?
• What are the forecasted sales of INVOKANA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging products available and how are these giving competition to INVOKANA for DKD?
• Which are the late-stage emerging therapies under development for the treatment of DKD?